-
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
-
Aliabbas A. Husain, Andreas Kupz, Rajpal S. Kashyap
-
Epidemiol Health. 2021;43:e2021022. Published online April 7, 2021
-
DOI: https://doi.org/10.4178/epih.e2021022
-
-
18,016
View
-
463
Download
-
5
Web of Science
-
7
Crossref
-
 Abstract
Summary
 PDF
-
Abstract
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
-
Summary
Key Message
India is regarded as highest drug-resistant TB burden country accounting for estimated 27% of global cases. Challenge of addressing drug resistant TB is critical for India to achieve TB elimination targets of National TB program. Several heterogeneous factors have mediated the success of DR-TB management in India. In this article, we discuss, in brief, some of the major challenges and implications associated with reducing the growing DR-TB epidemic in India.
-
Citations
Citations to this article as recorded by  - Enhancing Tuberculosis Treatment Adherence: Evaluating the Efficacy of the Support for Treatment Adherence and Medication Protocols (STAMP) Device for Automatic Dispensing and Real-Time Medication Monitoring
Simon Chandramohan Jason Charles, Krishna Anusha, Krishna Mahesh, Ramachandran Ramasubramanian, Perumal Kaliraj, Vimalraj Selvaraj
Cureus.2024;[Epub] CrossRef - Rifampicin-resistant Tuberculosis: A Global Health Dilemma
Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Mainul Haque
Advances in Human Biology.2024; 14(2): 87. CrossRef - Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases
Aparna Bhanushali, Sachin Atre, Preethi Nair, Geethanjali Anilkumar Thandaseery, Sanchi Shah, Sanjana Kuruwa, Amrutraj Zade, Chaitali Nikam, Mangala Gomare, Anirvan Chatterjee, Arryn Craney
Microbiology Spectrum.2024;[Epub] CrossRef - Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study
Priyanka Joshi, Krishna G Singh, Vishal Patidar, Vikas Gupta
Cureus.2024;[Epub] CrossRef - Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends
Hui-Wen Song, Jian-Hua Tian, Hui-Ping Song, Si-Jie Guo, Ye-Hong Lin, Jin-Shui Pan
Frontiers in Public Health.2024;[Epub] CrossRef - Double trouble: compounding effects of COVID-19 pandemic and antimicrobial resistance on drug resistant TB epidemiology in India
Aliabbas A. Husain, Rajpal Singh Kashyap
Frontiers in Public Health.2023;[Epub] CrossRef - Snapshot of Mycobacterium tuberculosis Phylogenetics from an Indian State of Arunachal Pradesh Bordering China
Shiv kumar Rashmi Mudliar, Umay Kulsum, Syed Beenish Rufai, Mika Umpo, Moi Nyori, Sarman Singh
Genes.2022; 13(2): 263. CrossRef
|
KSE
